Antifibrinolytics for Bleeding Prevention in Haematological Disorders: A Review
Tranexamic acid, an antifibrinolytic medication, probably makes little or no difference in preventing moderate or severe bleeding for patients suffering from thrombocytopenia and other blood disorders, according to an updated review current to January 2025.
Low platelet counts frequently threaten patients undergoing treatment for haematological cancers like leukaemia, lymphoma, and myeloma, or those experiencing bone marrow failure. While platelet transfusions remain the standard approach to manage this bleeding risk, these transfusions carry documented hazards ranging from mild fevers to life-threatening infections transmitted through donated blood. Antifibrinolytic agents such as tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) were investigated as a potential method to stabilise clots and reduce reliance on transfusions.
Key Clinical Takeaways:
- Tranexamic acid compared to placebo likely shows little to no impact on reducing moderate or severe bleeding events in patients with thrombocytopenia.
- The available clinical literature lacks sufficient data to determine whether epsilon aminocaproic acid decreases bleeding or transfusion requirements.
- Evidence quality remains limited due to small participant numbers across existing randomised trials, leaving questions regarding thrombosis risks and mortality unresolved.
Clinical Trial Evidence and Methodology
The updated review evaluated eight studies encompassing a total of 1,041 participants. Out of these trials, six investigated tranexamic acid against a placebo, one compared epsilon aminocaproic acid to an absence of EACA, and a single trial contrasted EACA with standard platelet transfusion protocols. Seven studies enrolled adult cohorts, while one focused on pediatric patients. Funding for these investigations varied: five studies received support from governmental, university, or non-pharmaceutical entities, one relied on pharmaceutical backing, and two did not disclose funding details.
Statistical analysis of the data revealed that TXA administration likely generates little to no difference in the number of patients experiencing moderate bleeding or worse. Similarly, the medication appears to confer little or no measurable reduction in severe, life-threatening haemorrhages or dangerous vascular blood clots known as thromboembolism. Data regarding mortality rates and serious adverse events remained insufficient to draw definitive clinical conclusions.
Limitations in Existing Haematological Research
Methodological constraints continue to hamper clinical certainty in this field of study. The Cochrane review highlights that the total volume of published trials remains too low to establish definitive treatment guidelines. Furthermore, severe clinical outcomes such as mortality and deep vein thrombosis occurred infrequently within the trial populations, widening confidence intervals and obscuring clear risk-benefit profiles.
The two studies examining epsilon aminocaproic acid failed to yield adequate statistical reporting for inclusion in quantitative synthesis, leaving the clinical utility of EACA largely unverified.
Future Trajectory of Antifibrinolytic Research
As researchers look beyond the January 2025 evidence cutoff, establishing clear safety and efficacy parameters for lysine analogues in thrombocytopenic populations requires larger, adequately powered multicenter randomised controlled trials. Until such data emerges, clinicians must carefully weigh the marginal prophylactic benefits of medications like tranexamic acid against the established risks of thromboembolism and the ongoing limitations of current trial designs.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.